Oswald Sonntag
Research Subjects
Oswald Sonntag has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Lippi
Section of Clinical Biochemistry , University of Verona , Verona , Italy
6 shared publications - Charles René Lefèvre
Laboratoire de Biochimie-Toxicologie , CHU de Rennes , Rennes , France
3 shared publications - Hikmet Can Çubukçu
Department of Medical Biochemistry , Sincan Training and Research Hospital , Ankara , Türkiye
3 shared publications - Mario Plebani
Department of Laboratory Medicine , University Hospital – Padova, University of Padova , Padova , Italy
3 shared publications - Nathan Lorde
Department of Clinical Chemistry , University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK
3 shared publications - Amitava Dasgupta
Department of Pathology and Laboratory Medicine , University of Kansas Medical Center , Kansas City , USA
2 shared publications
Latest Publications
- 11 November 2026
- Published by Walter de Gruyter GmbH in Diagnosis
Comments on Gordon’s proposal for outcome-based optimal laboratory intervals
- 11 November 2026
- Published by Walter de Gruyter GmbH in Diagnosis
Comments on Gordon’s proposal for outcome-based optimal laboratory intervals
- 28 October 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Why do hemolysis interference studies produce different results? A proposal for standardized experimental design and reporting
Background: Hemolysis is a major preanalytical source of laboratory interference, but methods used to experimentally generate hemolyzed specimens are poorly standardized. Content: Different lysis procedures, blood sources, cellular compositions, hemolysate volumes, control designs, and time-to-analysis can influence results independently of free hemoglobin concentration. The amount and composition of intracellular material released may also vary with erythrocyte, leukocyte, and platelet characteristics. Therefore, identical hemolysis indices do not necessarily represent equivalent experimental interferents. Summary: Hemolysis interference studies should clearly distinguish the interferent, its method of generation, and its measurement. Detailed reporting of specimen preparation and experimental conditions is essential for reproducibility and comparison between studies. Outlook: Harmonized hemolysate preparation and reporting, together with assessment at clinically relevant measurand concentrations and, when appropriate, multiple time points, would improve the reliability of hemolysis thresholds and laboratory decision-making.
- 28 October 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Why do hemolysis interference studies produce different results? A proposal for standardized experimental design and reporting
Background: Hemolysis is a major preanalytical source of laboratory interference, but methods used to experimentally generate hemolyzed specimens are poorly standardized. Content: Different lysis procedures, blood sources, cellular compositions, hemolysate volumes, control designs, and time-to-analysis can influence results independently of free hemoglobin concentration. The amount and composition of intracellular material released may also vary with erythrocyte, leukocyte, and platelet characteristics. Therefore, identical hemolysis indices do not necessarily represent equivalent experimental interferents. Summary: Hemolysis interference studies should clearly distinguish the interferent, its method of generation, and its measurement. Detailed reporting of specimen preparation and experimental conditions is essential for reproducibility and comparison between studies. Outlook: Harmonized hemolysate preparation and reporting, together with assessment at clinically relevant measurand concentrations and, when appropriate, multiple time points, would improve the reliability of hemolysis thresholds and laboratory decision-making.
- 29 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
The severity of harm score database: an evidence-based foundation for laboratory test risk analysis
Background: Patient risk management has become central to clinical laboratory quality standards, including the Clinical and Laboratory Standards Institute (CLSI) EP23 2nd edition (CLSI EP23-ED2), International Organization for Standardization (ISO) 15189:2022, ISO 22367:2026, and ISO 14971:2019. A key component of risk analysis is estimating the severity of harm (SoH) that may result from erroneous laboratory results. We present here the Severity of Harm Evidence Database, a structured, multi-study resource that integrates survey-based SoH assessments from the published independent studies. The database provides ordinal distributions and pooled SoH for 196 unique laboratory tests. Methods: A canonical five-level scale (negligible, minor, serious, critical, catastrophic) was adopted, aligned with ISO 14971:2019. For the 19 tests common to both studies, direct count pooling was performed by summing category-level respondent counts. Wilson score confidence intervals were calculated for all proportions. The database is organized into nine relational sheets and is accompanied by an interactive web application. Results: Out of the 196 tests covered, 19 have pooled estimates from both studies (total n=781 respondents). Pooled analysis confirms that cardiac biomarkers, blood gases, coagulation parameters, electrolytes (potassium, sodium), and therapeutic drug concentrations (digoxin, lithium) consistently receive the highest severity ratings, while certain endocrine markers receive lower scores. Conclusions: The SoH evidence database offers the first publicly available, structured repository of SoH assessments for clinical laboratory tests. It supports compliance with risk management requirements, informs risk-based strategies per CLSI EP23-ED2, and provides an evidence-based foundation for laboratory risk analysis.
- 29 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
The severity of harm score database: an evidence-based foundation for laboratory test risk analysis
Background: Patient risk management has become central to clinical laboratory quality standards, including the Clinical and Laboratory Standards Institute (CLSI) EP23 2nd edition (CLSI EP23-ED2), International Organization for Standardization (ISO) 15189:2022, ISO 22367:2026, and ISO 14971:2019. A key component of risk analysis is estimating the severity of harm (SoH) that may result from erroneous laboratory results. We present here the Severity of Harm Evidence Database, a structured, multi-study resource that integrates survey-based SoH assessments from the published independent studies. The database provides ordinal distributions and pooled SoH for 196 unique laboratory tests. Methods: A canonical five-level scale (negligible, minor, serious, critical, catastrophic) was adopted, aligned with ISO 14971:2019. For the 19 tests common to both studies, direct count pooling was performed by summing category-level respondent counts. Wilson score confidence intervals were calculated for all proportions. The database is organized into nine relational sheets and is accompanied by an interactive web application. Results: Out of the 196 tests covered, 19 have pooled estimates from both studies (total n=781 respondents). Pooled analysis confirms that cardiac biomarkers, blood gases, coagulation parameters, electrolytes (potassium, sodium), and therapeutic drug concentrations (digoxin, lithium) consistently receive the highest severity ratings, while certain endocrine markers receive lower scores. Conclusions: The SoH evidence database offers the first publicly available, structured repository of SoH assessments for clinical laboratory tests. It supports compliance with risk management requirements, informs risk-based strategies per CLSI EP23-ED2, and provides an evidence-based foundation for laboratory risk analysis.
- 27 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (12) , e298-e300
On repeating out-of-control quality control measurements in medical laboratories
- 27 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (12) , e298-e300
On repeating out-of-control quality control measurements in medical laboratories
- Open Access
- 19 February 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (7) , 1527-1560
Establishing the laboratory error database: rationale, methodology, and a practical example
Laboratory errors represent a critical yet underestimated threat to patient safety, with 26–30 % of reported errors adversely affecting patient care. Despite extensive scientific literature, no sustainable, open-access platform exists that allows laboratory professionals to rapidly access comprehensive information on error types, bias magnitudes, and clinical risks for specific analytes and platforms. To address this gap, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) established the Committee on Laboratory Error Database (C-LED). C-LED aims to develop and maintain a continuously updated, evidence-based database covering laboratory errors, their impacts on test results, severity of potential harm, and supporting references across multiple analytical platforms and assay generations. C-LED employs a novel three-pillar information procurement strategy encompassing literature knowledge, manufacturer data, and supplementary sources, including incident reports and external quality assessment data. The literature procurement utilizes an innovative two-stage AI-driven approach: Stage 1 employs Claude Desktop with Model Context Protocol integration for systematic PubMed and Crossref screening, while Stage 2 combines Google NotebookLM and Claude Desktop for comprehensive full-text data extraction using standardized prompts and metadata structures. A case study examining haemolysis interference on cardiac troponin measurements demonstrates the approach’s value, revealing platform-specific patterns ranging from minimal interference in contemporary high-sensitivity assays to severe bias in older platforms. The study identified that interference magnitude is concentration-dependent, with greater impacts at lower analyte baselines. By combining institutional governance, AI-driven efficiency, and multiple information sources, C-LED aim to establish a sustainable framework for database construction, ultimately enhancing diagnostic accuracy and patient safety globally.
- 19 February 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (7) , 1527-1560
Open AccessEstablishing the laboratory error database: rationale, methodology, and a practical example
Laboratory errors represent a critical yet underestimated threat to patient safety, with 26–30 % of reported errors adversely affecting patient care. Despite extensive scientific literature, no sustainable, open-access platform exists that allows laboratory professionals to rapidly access comprehensive information on error types, bias magnitudes, and clinical risks for specific analytes and platforms. To address this gap, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) established the Committee on Laboratory Error Database (C-LED). C-LED aims to develop and maintain a continuously updated, evidence-based database covering laboratory errors, their impacts on test results, severity of potential harm, and supporting references across multiple analytical platforms and assay generations. C-LED employs a novel three-pillar information procurement strategy encompassing literature knowledge, manufacturer data, and supplementary sources, including incident reports and external quality assessment data. The literature procurement utilizes an innovative two-stage AI-driven approach: Stage 1 employs Claude Desktop with Model Context Protocol integration for systematic PubMed and Crossref screening, while Stage 2 combines Google NotebookLM and Claude Desktop for comprehensive full-text data extraction using standardized prompts and metadata structures. A case study examining haemolysis interference on cardiac troponin measurements demonstrates the approach’s value, revealing platform-specific patterns ranging from minimal interference in contemporary high-sensitivity assays to severe bias in older platforms. The study identified that interference magnitude is concentration-dependent, with greater impacts at lower analyte baselines. By combining institutional governance, AI-driven efficiency, and multiple information sources, C-LED aim to establish a sustainable framework for database construction, ultimately enhancing diagnostic accuracy and patient safety globally.